##### 



Exhibit 99.1

NEWS RELEASE

UROPLASTY, INC. REPORTS SECOND QUARTER FINANCIAL RESULTS
ENDING SEPTEMBER 30, 2003

Wednesday, November 12, 2003

MINNEAPOLIS, MN Uroplasty, Inc. (OTC: UPST  news) reports its worldwide
financial results for the second quarter ended September 30, 2003 with total
net sales of all products at $1,175,073, representing a 9% decrease when
compared to net sales of $1,288,875 for the second quarter ended September 30,
2002. During the six months ended September 30, 2003, net sales of all products
were $2,534,662, representing a 2% decrease when compared to net sales of
$2,597,974 during the six months ended September 30, 2002. The Macroplastique®
product line accounts for approximately 84% of total net sales during the
periods presented. The sales decrease is the result of a decrease in unit
sales, offset by favorable fluctuations in foreign currency exchange rates
between the U.S. Dollar (the functional reporting currency) and the Euro and
the British Pound (currencies of the Companys subsidiaries). Excluding the
fluctuations in foreign currency exchange rates, the sales decrease is
approximately 18% for the three months ended September 30, 2003 and
approximately 16% for the six months then ended. Management believes the
decrease in sales is related to increased competition and healthcare reform in
many European countries with procedures being limited or rationed to decrease
overall costs to the health system. Gross profit was $900,887 and $933,586 for
the quarters ended September 30, 2003 and 2002, respectively, or 77% and 72% of
net sales. Gross profit was $1,854,889 and $1,822,971 for the six months ended
September 30, 2003 and 2002, respectively, or 73% and 70% of net sales. Gross
profit in any one period is highly variable depending on unit sales and
utilization of manufacturing capacity. The second quarter had a net loss of
$(393,720) compared to net loss of $(116,547) for the same period last year.
The six months period had a net loss of $(843,839) compared to net income of
$333,238 for the same period last year. The reduced profitability in the
current-year three and six months ended September 30, 2003 was largely due to a
prior-year $407,333 gain from currency exchange rates and increased operating
expenses in the current year.

Research and development expenses decreased $61,600, or 13%, from $481,790
during the second quarter of fiscal 2003 to $420,190 during the second quarter
of fiscal 2004 and decreased 14% from $1,001,208 during the six months ended
September 30, 2002 to $858,763 during the six months ended September 30, 2003.
The decrease in R&D expense resulted from a decrease in clinical costs due to
the completion of the patient enrollment and treatment phases in the Companys
ongoing multi-center IDE clinical trial for female stress urinary incontinence.
General and administrative expenses increased from $299,661 during the second
quarter of fiscal 2003 to $456,769 during the second quarter of fiscal 2004 and
increased from $572,128 during the six months ended September 30, 2002 to
$922,045 during the six months ended September 30, 2003. Increased costs for
European pension plans, consulting, legal, and shareholders expenses, combined
with general price increases and fluctuations in foreign currency exchange
rates, caused the increase in G&A expenses. Selling and marketing costs
increased 32% from $259,664 during the second quarter of fiscal 2003 to
$342,394 during the second quarter of fiscal 2004 and increased 49% from
$513,827 during the six months ended September 30, 2002 to $764,804 during the
six months ended September 30, 2003. Increased costs resulted from additional
staff, increased travel, additional trade-shows, conventions and congresses,
and marketing materials, all reflecting a more aggressive sales strategy.
Additional contributors include general price increases, and fluctuations in
foreign currency exchange rates.

CEO Dan Holman states, Each quarter now is a major step for Uroplasty as we
approach nearer to the regulatory approval to market Macroplastique® in the
U.S. as a solution to female urinary incontinence. Both the patient enrollment
and treatment phases of the FDA IDE study are complete and now we continue with
the final patient follow-up stage.





---



##### 



Holman also states, Our European sales provide us revenue to fund, to a large
extent, our U.S. trials, and in Europe to fund research and market a
multiplicity of applications of Macroplastique. The European, Canadian, and
Australian launch of PTP implants, a soft tissue-bulking agent for the
minimally invasive outpatient treatment of fecal incontinence, is just an
example of this multiplicity of applications outside of Macroplastiques
urological indications. This underlines the fact that Macroplastique is a
platform technology capable of supporting and growing Uroplasty into a major
force in the incontinence and related markets.

As Uroplasty comes closer to the conclusion of its U.S. clinical study and a
measurably intensified, substantially broadened worldwide marketing campaign
for Macroplastique, we are concurrently magnifying our efforts to communicate
our story to the investment community. This is being accomplished in
partnership with CCRI Financial Group, a well known investor relations firm
with a national presence. Building shareholder value has, from the beginning,
been a continuing commitment for Uroplasty management.

***

Uroplasty is a medical device company that develops, manufactures and markets a
family of injectable implant products used for soft-tissue augmentation for
specific indications in urology, urogynecology, colon and rectal,
otolaryngology and plastic surgery markets. The Companys products offer
physicians and their patients a minimally invasive treatment option for urinary
incontinence, vesicoureteral reflux, fecal incontinence, vocal cord
rehabilitation and dermal augmentation. Uroplastys products are CE marked for
these indications and sold in markets outside the United States.

Summary of Operations:

|                                           |         |   |                    |           |  |                  |           |           |         |  |           |           |  |  |           |           | 
|------------------------------------------ | ------- | - | ------------------ | --------- |  | ---------------- | --------- | --------- | ------- |  | --------- | --------- |  |  | --------- | --------- | 
|                                           |         |   | Three Months Ended |           |  | Six Months Ended |          
|                                           |         |   |                    |           |  |                  |          
|                                           |         |   | 9/30/03            |           |  | 9/30/02          |           |           | 9/30/03 |  |           | 9/30/02   | 
|                                           |         |   |                    |           |  |                  |           |           |         |  |           |           | 
|Net sales                                  |         | $ | 1,175,073          |           |  |                  | 1,288,875 |           |         |  | 2,534,662 |           |  |  | 2,597,974 |          
|Operating loss                             |         |   | (318,466           | )         |  |                  | (107,529  | )         |         |  | (690,723  | )         |  |  | (264,192  | )        
|Net income (loss)                          |         | $ | (393,720           | )         |  |                  | (116,547  | )         |         |  | (843,839  | )         |  |  | 333,238   |          
|Basic income (loss) per common share       |         | $ | (0.09              | )         |  |                  | (0.03     | )         |         |  | (0.19     | )         |  |  | 0.11      |          
|Diluted income (loss) per common share     |         | $ | (0.09              | )         |  |                  | (0.03     | )         |         |  | (0.19     | )         |  |  | 0.11      |          
|Weighted average common shares outstanding |         |   |                    |           |  |                  |           |           |         |  |           |           |  |  |           |          
|                                           | Basic   |   |                    | 4,487,222 |  |                  |           | 3,893,506 |         |  |           | 4,485,606 |  |  |           | 3,109,992 | 
|                                           | Diluted |   |                    | 4,487,222 |  |                  |           | 3,893,506 |         |  |           | 4,485,606 |  |  |           | 3,123,517 | 

Selected Consolidated Balance Sheet Data

|       |                                                    |  |                    |           |  |                |  |           | 
|------ | -------------------------------------------------- |  | ------------------ | --------- |  | -------------- |  | --------- | 
|       |                                                    |  | September 30, 2003 |           |  | March 31, 2003 | 
|       |                                                    |  |                    |           |  |                | 
|Assets |                                                    |  |                    |           |  |                |  |          
|       | Current assets                                     |  | $                  | 4,609,458 |  |                |  | 4,988,843 | 
|       | Property, plant, and equipment, net                |  |                    | 874,017   |  |                |  | 833,234   | 
|       | Intangible assets, net of accumulated
amortization |  |                    | 51,854    |  |                |  | 48,214    | 
|       |                                                    |  |                    |           |  |               
|       | Total assets                                       |  | $                  | 5,535,329 |  |                |  | 5,870,291 | 
|       |                                                    |  |                    |           |  |               





---



##### 



|                                     |                                            |                                     |   |           |         |  |  |           |         | 
|------------------------------------ | ------------------------------------------ | ----------------------------------- | - | --------- | ------- |  |  | --------- | ------- | 
|Liabilities and Shareholders Equity |                                            |                                     |   |           |         |  |  |          
|                                     | Current liabilities:                       |                                     |   |           |         |  |  |           |        
|                                     |                                            | Accounts payable                    |   | $         | 329,527 |  |  |           | 199,673 | 
|                                     |                                            | Income tax payable                  |   |           | 154,198 |  |  |           |        | 
|                                     |                                            | Accrued liabilities                 |   |           | 237,008 |  |  |           | 349,937 | 
|                                     |                                            | Current maturities  long-term debt |   |           | 40,092  |  |  |           | 37,502  | 
|                                     |                                            |                                     |   |           |         |  |  |          
|                                     | Total current liabilities                  |                                     |   | 760,825   |         |  |  | 587,112   |        
|                                     | Long-term debt  less current maturities   |                                     |   | 474,713   |         |  |  | 462,787   |        
|                                     |                                            |                                     |   |           |         |  |  |          
|                                     | Total liabilities                          |                                     |   | 1,235,538 |         |  |  | 1,049,899 |        
|                                     | Shareholders equity                       |                                     |   | 4,299,791 |         |  |  | 4,820,392 |        
|                                     |                                            |                                     |   |           |         |  |  |          
|                                     | Total liabilities and shareholders equity |                                     | $ | 5,535,329 |         |  |  | 5,870,291 |        
|                                     |                                            |                                     |   |           |         | 

The Private Securities Litigation Reform Act of 1995 provides a safe harbor
for certain forward-looking statements. This press release contains
forward-looking statements, including our internal projections of anticipated
fiscal 2004 operating results, which reflect our views regarding future events
and financial performance. These forward-looking statements are subject to
certain risks and uncertainties, including those identified below, which could
cause actual results to differ materially from historical results or those
anticipated. The words aim, believe, expect, anticipate, intend,
estimate and other expressions which indicate future events and trends
identify forward-looking statements. Actual future results and trends may
differ materially from historical results or those anticipated depending upon a
variety of factors, including, but not limited to: the effect of government
regulation, including when and if we receive approval for marketing of our
products in the United States; the impact of international currency
fluctuations on our cash flows and operating results; the impact of
technological innovation and competition; acceptance of our products by
physicians and patients, our reliance on a single product for most of our
current sales; our intellectual property and the ability to prevent
competitors from infringing our rights; the ability to receive third party
reimbursement for our products; the results of our current human clinical
trial; our continued losses and the possible need to raise additional capital
in the future; our ability to manage our international operations; our
ability to hire and retain key technical and sales personnel; our dependence on
key suppliers; future changes in applicable accounting rules; and volatility
in our stock price.

Uroplasty, Inc. stock is traded on the OTC Bulletin Board system under the
symbol UPST.OB.

FOR FURTHER INFORMATION: visit Uroplastys web page at www.uroplasty.com or
contact Mr. Holman.

UROPLASTY, INC.
Daniel G. Holman, President / CEO
2718 Summer Street NE, Minneapolis, MN 55413-2820
Tel: 612-378-1180
Fax: 612-378-2027
E-mail: danielh@uroplasty.com